Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 5.4%

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) dropped 5.4% during mid-day trading on Wednesday . The company traded as low as $13.11 and last traded at $13.20. Approximately 90,213 shares traded hands during trading, a decline of 90% from the average daily volume of 904,461 shares. The stock had previously closed at $13.95.

Analysts Set New Price Targets

A number of equities analysts recently commented on STOK shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Monday, May 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. boosted their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. Finally, Wedbush increased their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Stock Performance

The company has a 50 day simple moving average of $13.76 and a two-hundred day simple moving average of $9.30.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.03. The company had revenue of $4.22 million during the quarter, compared to the consensus estimate of $3.33 million. On average, equities analysts predict that Stoke Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the completion of the transaction, the insider now owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently modified their holdings of the company. Redmile Group LLC raised its position in Stoke Therapeutics by 93.2% during the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock valued at $68,486,000 after purchasing an additional 2,447,543 shares in the last quarter. Lynx1 Capital Management LP raised its holdings in shares of Stoke Therapeutics by 25.0% in the first quarter. Lynx1 Capital Management LP now owns 3,696,820 shares of the company’s stock valued at $49,907,000 after acquiring an additional 739,902 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Stoke Therapeutics by 65.9% in the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after acquiring an additional 1,338,309 shares during the period. Vanguard Group Inc. grew its holdings in Stoke Therapeutics by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after acquiring an additional 67,052 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in Stoke Therapeutics by 514.7% during the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after purchasing an additional 291,443 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.